Navigation Links
Southwest Oncology Network (SWON) Selects Diplomat Specialty Pharmacy for Development and Launch of SWON-Rx, an Oral Oncology Medication Management Platform
Date:5/18/2010

SWARTZ CREEK, Mich., May 18 /PRNewswire/ -- Diplomat Specialty Pharmacy (Diplomat), the largest privately owned specialty pharmacy in the country, announced today that effective May 11, 2010, they have entered into a joint agreement with Southwest Oncology Network (SWON) to create SWON-Rx, a comprehensive specialty pharmacy support program to help practices manage oral oncology medications.  SWON-Rx will create programs that support SWON members' efforts to achieve optimal clinical outcomes for their patients.    

SWON is a professional limited liability company whose members are physicians and physician practices whose patients routinely require high-cost, specialty pharmaceuticals specifically for treatment of cancer.  SWON currently consists of 65 oncology practices throughout the United States, representing approximately 272 oncologists.

The joint agreement between SWON and Diplomat will provide SWON members access to Diplomat's Oncology Navigator™ program.  The Oncology Navigator™ Program incorporates over 35 years of experience in providing clinical and reimbursement solutions to patients with oncologic and hematologic disorders.  

"SWON selected Diplomat because of their patient centric reputation in the industry, their high level of customer service, and their commitment to helping oncology patients get the medications they need to obtain optimal clinical outcomes," stated  Mark Colangelo, SWON Vice President.  "Diplomat has unique expertise and dedicated resources that assist patients in reducing the financial burdens associated with these life-sustaining medications. SWON member practices value the support this provides their patients and their staff."

"Diplomat will be SWON's oral oncology Rx solution," stated Mark Neville, Vice President of Sales & Marketing.  "With the high number of new oral therapeutic options that have been FDA approved over the past few years, Diplomat's Oncology Navigator™  has dedicated the required resources to help SWON patients and physicians gain access to these needed medications regardless of the changing reimbursement landscape."

"The partnership between SWON and Diplomat will give us the opportunity to take the patient support services of our Oncology Navigator™ program to a new level," said Phil Hagerman, President & CEO of Diplomat Specialty.  "SWON-Rx was developed to create an improved system of patient care that encompasses all stakeholders in the fight against cancer."

About Diplomat Specialty Pharmacy

Michigan-based Diplomat Specialty Pharmacy, founded in 1975, is the nation's largest privately held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Crohn's, Hemophilia, Growth Hormone and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio-Identical Hormone Therapy and Specialty Compounding. The company also specializes in disease management programs for chronic kidney disease patients. With locations in Flint, Swartz Creek and Grand Rapids, MI; Cleveland, OH; Chicago, IL; Ft. Lauderdale, Florida; and Los Angeles. Learn more about Keeping Patients Healthier…Longer™ at www.diplomatpharmacy.com

For more information contact:

Kathy Karns

kkarns@diplomatpharmacy.com

810.720.4452


'/>"/>
SOURCE Diplomat Specialty Pharmacy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
8. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
9. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
10. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- According to the latest market report published ... Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type Segment ... 2024 " the global automated endoscope reprocessors market was valued at US$ 740.6 ... CAGR of 7.2% during an eight-year forecast period 2016-2024, to ... ...
(Date:12/2/2016)... ATLANTA , Dec. 2, 2016 Quantum ... screening and expert radiologist interpretation directly to women at ... partners with corporations, such as Delta Air Lines and ... cancer screening as a component of wellness initiatives. ... women of SunTrust. It enables them to have a ...
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... ... 2016 , ... Advanced Inc., a leading provider of travel therapy and travel ... serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served ... and operational leadership experience to Advanced Inc. He began his career in finance at ...
(Date:12/2/2016)... PITTSBURGH, PA (PRWEB) , ... December 02, 2016 , ... ... or struggling through rehabilitation of an injury, patients must find the one that works ... for his pain, he created a machine that worked and decided to share it ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):